A clinical study demonstrates that rapid whole-genome sequencing (rWGS) reduces pediatric cancer diagnosis turnaround times from a mean of 42 days to just 3 days. Utilizing Illumina's TruPath Genome technology, rWGS detected 95% of clinically actionable variants across 37 distinct cancer types, improving care for 49% of prospectively analyzed children by enabling targeted treatments and avoiding invasive procedures. This builds on prior genomic research, such as a 2023 study that diagnosed 41% of rare pediatric genetic disorders.
Reduction in diagnostic turnaround times
- ▪The turnaround time for standard Genomic Medicine Service sequencing in England typically ranges from two to six weeks, with a national average of four to six weeks.
- ▪Rapid whole-genome sequencing reduced the mean turnaround time for pediatric cancer clinical reports from 42 days under standard Genomic Medicine Service sequencing to 3 days.
Design of the rapid sequencing study
- ▪The rapid whole-genome sequencing study deployed Illumina's TruPath Genome technology on extracted DNA from solid tumors and blood, or crude lysate from bone marrow and peripheral blood samples.
- ▪A clinical study of 54 children with suspected or confirmed cancer recruited between April 2023 and March 2025 evaluated the feasibility of rapid whole-genome sequencing to enhance pediatric cancer diagnostics.
Clinical benefits for pediatric patients
- ▪In the prospective cohort of the rapid whole-genome sequencing study, 17 out of 35 children (49%) experienced measurable improvements in care, such as reduced time to diagnosis or avoidance of unnecessary procedures.
- ▪Review of retrospective cases by three independent clinicians in the rapid whole-genome sequencing study indicated that 9 out of 19 pediatric cancer patients (47%) could have benefited if results had been available at presentation.
- ▪Clinical applications of rapid whole-genome sequencing in the study enabled targeted treatments, such as MEK pathway inhibition for a patient with pancreatic acinic cell carcinoma, and helped other patients avoid unnecessary invasive procedures.
Variant detection accuracy
- ▪Rapid whole-genome sequencing captured 147 of 155 (95%) clinically actionable variants across 104 pediatric cancer samples representing 37 hematological/solid tumor entities; standard Genomic Medicine Service sequencing detected 138 (89%), leaving 17 only detected by rapid.
- ▪The eight clinically actionable variants missed by rapid whole-genome sequencing were attributed to tumor heterogeneity or low variant allele frequency.
Technical advantages of rapid sequencing
- ▪The rapid whole-genome sequencing method achieved a median coverage depth of 137x for tumor samples and 84x for germline samples, compared to 97x and 42x respectively for standard Genomic Medicine Service sequencing.
- ▪The rapid whole-genome sequencing method bypassed DNA extraction and library synthesis by allowing direct application of DNA or crude lysate onto the flowcell surface.
Findings on developmental disorders
- ▪In the Deciphering Developmental Disorders study published in April 2023, analyzing an entire parent-offspring trio yielded the highest chance of diagnosis, with an odds ratio of 4.70 compared to singletons.
- ▪A study by the Deciphering Developmental Disorders group published in The New England Journal of Medicine in April 2023 diagnosed approximately 41% of 13,449 pediatric patients with severe developmental disorders.
Debatable claims
- ▪The lack of diverse ancestry-matched controls makes genomic sequencing significantly less effective for minority pediatric patients
- ▪Rapid genetic sequencing is reliable enough to replace invasive diagnostic biopsies for pediatric cancer patients
- ▪NHS England should replace standard Genomic Medicine Service sequencing with rapid whole-genome sequencing for pediatric cancer
- ▪The speed of rapid whole-genome sequencing justifies the risk of missing some actionable genetic variants
Story comments
Loading comments…